Elekta

AGM Information • Oct 24, 2012

Press release Stockholm, October 24, 2012

Elekta's Nomination Committee for the Annual General Meeting 2013

In accordance with the decision at the Annual General Meeting on September 4, 2012, Elekta's Chairman of the Board has contacted the company's largest shareholders to form a Nomination Committee. Subsequently, the shareholders agreeing to participate in the work of the Nomination Committee has each appointed a member.

The Nomination Committee that will prepare matters prior to the Annual General Meeting 2013 consists of Anders Oscarsson, AMF Insurance and Funds, Åsa Nisell, Swedbank Robur funds, Ossian Ekdahl, Första AP-Fonden, Laurent Leksell, representing his private and companies' holdings, and Akbar Seddigh, Chairman of the Board. The Nomination Committee will appoint one of the members as Chairman.

Combined, the shareholders in the Nomination Committee represented approximately 38 percent of the votes in Elekta AB on September 28, 2012.

Shareholders wishing to submit proposals to Elekta's Nomination Committee can do so by e-mail at valberedningen@elekta.com or by letter to: Elekta AB, Nomination Committee, Box 7593, SE-103 93 Stockholm, Sweden.

The Committee's assignment remains effective until a new Nomination Committee is appointed.

******

For further information, please contact:

Johan Andersson Melbi, Investor Relations Manager, Elekta AB. Tel: +46 702 100 451, email: johan.anderssonmelbi@elekta.com.

The above information is such that Elekta AB (publ) shall make public in accordance with the Securities Market Act and/or the Financial Instruments Trading Act. The information was published at 08.00 CET on October 24, 2012.

About Elekta

Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy, radiosurgery and brachytherapy, as well as workflow enhancing software systems across the spectrum of cancer care. Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives.

Today, Elekta solutions in oncology and neurosurgery are used in over 6,000 hospitals worldwide. Elekta employs around 3,400 employees globally. The corporate headquarters is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. Website: www.elekta.com.